前列腺健康指数在“灰区”前列腺癌中的研究进展
Research Progress on Prostate Health Index (PHI) in “Grey Zone” Prostate Cancer
摘要: 前列腺癌是男性最常见的泌尿系统恶性肿瘤，且它的发病率呈增高的趋势，所以其早期诊断对治疗效果和患者预后至关重要。目前，前列腺特异性抗原(PSA)检测是最常用的前列腺癌筛查指标，虽然其广泛应用，但在PSA灰区(4~10 ng/mL)的患者中，因特异性较低的缘故，常导致过度检查和治疗。而前列腺健康指数(PHI)作为一种新兴生物标志物，结合了总PSA (tPSA)、游离PSA (fPSA)和[−2]proPSA (p2PSA)，能够更准确地预测前列腺癌的存在。本文结合现有的文献，综述PHI在tPSA灰区前列腺癌诊断中的研究进展。
Abstract: Prostate cancer (PCa) is the most common urothelial malignancy in men, and its incidence is increasing. Consequently, early diagnosis is crucial for treatment efficacy and patient prognosis. Currently, prostate-specific antigen (PSA) testing is the most widely used screening tool for prostate cancer. Despite its extensive application, the low specificity of PSA within the “Grey Zone” (4~10 ng/mL) frequently leads to over-investigation and overtreatment in this patient population. The Prostate Health Index (PHI), an emerging biomarker that incorporates total PSA (tPSA), free PSA (fPSA), and [−2]proPSA (p2PSA), demonstrates enhanced accuracy in predicting the presence of prostate cancer. This review synthesizes current evidence to summarize the research progress on the utility of PHI in diagnosing prostate cancer among patients with tPSA levels in the Grey Zone.
文章引用：任远, 徐林钢, 李云祥, 谭小军. 前列腺健康指数在“灰区”前列腺癌中的研究进展[J]. 临床医学进展, 2025, 15(11): 2446-2454. https://doi.org/10.12677/acm.2025.15113369

参考文献

[1] Schröder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L.J., Ciatto, S., Nelen, V., et al. (2009) Screening and Prostate-Cancer Mortality in a Randomized European Study. New England Journal of Medicine, 360, 1320-1328. [Google Scholar] [CrossRef] [PubMed]
[2] 周金才, 居峰, 倪颖, 等. 前列腺健康指数在不同tPSA区间段诊断前列腺癌的临床价值研究[J]. 现代医学, 2023, 51(7): 918-922.
[3] Catalona, W.J., Partin, A.W., Sanda, M.G., Wei, J.T., Klee, G.G., Bangma, C.H., et al. (2011) A Multicenter Study of [−2]Pro-Prostate Specific Antigen Combined with Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range. Journal of Urology, 185, 1650-1655. [Google Scholar] [CrossRef] [PubMed]
[4] Lepor, A., Catalona, W.J. and Loeb, S. (2016) The Prostate Health Index: Its Utility in Prostate Cancer Detection. Urologic Clinics of North America, 43, 1-6. [Google Scholar] [CrossRef] [PubMed]
[5] Na, R., Ye, D., Qi, J., Liu, F., Helfand, B.T., Brendler, C.B., et al. (2017) Prostate Health Index Significantly Reduced Unnecessary Prostate Biopsies in Patients with PSA 2-10 ng/ml and PSA > 10 ng/ml: Results from a Multicenter Study in China. The Prostate, 77, 1221-1229. [Google Scholar] [CrossRef] [PubMed]
[6] Chiu, P.K.F., Roobol, M.J., Teoh, J.Y., Lee, W., Yip, S., Hou, S., et al. (2016) Prostate Health Index (PHI) and Prostate-Specific Antigen (PSA) Predictive Models for Prostate Cancer in the Chinese Population and the Role of Digital Rectal Examination-Estimated Prostate Volume. International Urology and Nephrology, 48, 1631-1637. [Google Scholar] [CrossRef] [PubMed]
[7] Mathieu, R., Castelli, C., Fardoun, T., Peyronnet, B., Shariat, S.F., Bensalah, K., et al. (2018) Cost Analysis of Prostate Cancer Detection Including the Prostate Health Index (PHI). World Journal of Urology, 37, 481-487. [Google Scholar] [CrossRef] [PubMed]
[8] Teoh, J.Y., Leung, C., Wang, M.H., Chiu, P.K., Yee, C., Ng, C., et al. (2020) The Cost-Effectiveness of Prostate Health Index for Prostate Cancer Detection in Chinese Men. Prostate Cancer and Prostatic Diseases, 23, 615-621. [Google Scholar] [CrossRef] [PubMed]
[9] Loeb, S., Sanda, M.G., Broyles, D.L., Shin, S.S., Bangma, C.H., Wei, J.T., et al. (2015) The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer. Journal of Urology, 193, 1163-1169. [Google Scholar] [CrossRef] [PubMed]
[10] Agnello, L., Vidali, M., Giglio, R.V., Gambino, C.M., Ciaccio, A.M., Lo Sasso, B., et al. (2022) Prostate Health Index (PHI) as a Reliable Biomarker for Prostate Cancer: A Systematic Review and Meta-Analysis. Clinical Chemistry and Laboratory Medicine (CCLM), 60, 1261-1277. [Google Scholar] [CrossRef] [PubMed]
[11] 李郑立, 刘贺亮, 徐燕. TPSA与FPSA并结合FPSA/TPSA比值对前列腺疾病的鉴别诊断价值[J]. 河北医科大学学报, 2011, 32(9): 1086-1088.
[12] 贾伟, 吴波, 陈骞, 等. 前列腺健康指数及f/tPSA对于PSA “灰区”前列腺癌诊断价值比较的Meta分析[J]. 中华腔镜泌尿外科杂志∙电子版, 2021, 15(6): 478-483.
[13] 潘良明, 沈菲菲, 马晓英, 等. 血清前列腺健康指数对tPSA灰区前列腺癌患者的诊断价值探讨[J]. 现代检验医学杂志, 2021, 36(1): 72-76, 99.
[14] Cheng, Y.T., Huang, C.Y., Chen, C.H., Chiu, S., Hong, J., Pu, Y., et al. (2020) Preoperative %p2PSA and Prostate Health Index Predict Pathological Outcomes in Patients with Prostate Cancer Undergoing Radical Prostatectomy. Scientific Reports, 10, Article No. 776. [Google Scholar] [CrossRef] [PubMed]
[15] Wu, B., Shao, Y., Lin, X., Hasi, C., Jia, W., Wang, D., et al. (2023) Comparisons of the Diagnostic Accuracy across Prostate Health Index, Prostate Health Index Density, and Percentage Free Prostate-Specific Antigen for Clinically Significant Prostate Cancer: A Prospective Diagnostic Study. Translational Andrology and Urology, 12, 425-432. [Google Scholar] [CrossRef] [PubMed]
[16] Lee, C.U., Lee, S.M., Chung, J.H., Kang, M., Sung, H., Jeon, H., et al. (2022) Clinical Utility of Prostate Health Index for Diagnosis of Prostate Cancer in Patients with PI-RADS 3 Lesions. Cancers, 14, Article No. 4174. [Google Scholar] [CrossRef] [PubMed]
[17] 曹志彬, 夏琴琴, 张华英, 等. 前列腺健康指数对前列腺特异性抗原处于灰区前列腺癌的诊断价值[J]. 临床和实验医学杂志, 2020, 19(16): 1741-1744.
[18] 刘聪, 周文杰, 魏凡杰, 等. 前列腺特异性抗原、前列腺健康指数与前列腺癌临床病理特征的相关性分析[J]. 中华养生保健, 2024, 42(9): 52-55.
[19] Kim, J.Y., Yu, J.H., Sung, L.H., Cho, D.Y., Kim, H. and Yoo, S.J. (2021) Usefulness of the Prostate Health Index in Predicting the Presence and Aggressiveness of Prostate Cancer among Korean Men: A Prospective Observational Study. BMC Urology, 21, Article No. 131. [Google Scholar] [CrossRef] [PubMed]
[20] Filella, X. and Giménez, N. (2012) Evaluation of [−2]ProPSA and Prostate Health Index (PHI) for the Detection of Prostate Cancer: A Systematic Review and Meta-Analysis. Clinical Chemistry and Laboratory Medicine (CCLM), 51, 729-739. [Google Scholar] [CrossRef] [PubMed]
[21] Kretschmer, A. and Tilki, D. (2017) Biomarkers in Prostate Cancer—Current Clinical Utility and Future Perspectives. Critical Reviews in Oncology/Hematology, 120, 180-193. [Google Scholar] [CrossRef] [PubMed]
[22] Liu, A.Q., Remmers, S., Lau, S., Yip, S., Leung, C., Mak, C.W., et al. (2021) Initial Prostate Health Index (PHI) and Phi Density Predicts Future Risk of Clinically Significant Prostate Cancer in Men with Initial Negative Prostate Biopsy: A 6-Year Follow-Up Study. Prostate Cancer and Prostatic Diseases, 25, 684-689. [Google Scholar] [CrossRef] [PubMed]
[23] Stephan, C., Jung, K., Lein, M., Rochow, H., Friedersdorff, F. and Maxeiner, A. (2021) PHI Density Prospectively Improves Prostate Cancer Detection. World Journal of Urology, 39, 3273-3279. [Google Scholar] [CrossRef] [PubMed]
[24] Huang, D., Wu, Y.S., Ye, D.W., Wu, Y., Ye, D., Qi, J., et al. (2020) Prostate Volume Does Not Provide Additional Predictive Value to Prostate Health Index for Prostate Cancer or Clinically Significant Prostate Cancer: Results from a Multicenter Study in China. Asian Journal of Andrology, 22, 539-543. [Google Scholar] [CrossRef] [PubMed]
[25] Ferro, M., De Cobelli, O., Lucarelli, G., Porreca, A., Busetto, G.M., Cantiello, F., et al. (2020) Beyond PSA: The Role of Prostate Health Index (PHI). International Journal of Molecular Sciences, 21, Article No. 1184. [Google Scholar] [CrossRef] [PubMed]
[26] Tosoian, J.J., Druskin, S.C., Andreas, D., Mullane, P., Chappidi, M., Joo, S., et al. (2017) Prostate Health Index Density Improves Detection of Clinically Significant Prostate Cancer. BJU International, 120, 793-798. [Google Scholar] [CrossRef] [PubMed]
[27] Garrido, M.M., Ribeiro, R.M., Pinheiro, L.C., Holdenrieder, S. and Guimarães, J.T. (2021) The Prostate Health Index (PHI) Density: Are There Advantages over PHI or over the Prostate-Specific Antigen Density? Clinica Chimica Acta, 520, 133-138. [Google Scholar] [CrossRef] [PubMed]
[28] 谭昌文, 雷震, 裴德龙, 等. 前列腺健康指数密度在前列腺癌诊断中的预测价值[J]. 吉林医学, 2023, 44(10): 2751-2754.
[29] Chen, Y., Xu, D., Ruan, M., Li, H., Lin, G. and Song, G. (2023) A Prospective Study of the Prostate Health Index Density and Multiparametric Magnetic Resonance Imaging in Diagnosing Clinically Significant Prostate Cancer. Investigative and Clinical Urology, 64, 363. [Google Scholar] [CrossRef] [PubMed]
[30] Chen, H., Qian, Y., Wu, Y., Shi, B., Zhou, J., Qu, F., et al. (2022) Modified Prostate Health Index Density Significantly Improves Clinically Significant Prostate Cancer (csPCa) Detection. Frontiers in Oncology, 12, Article ID: 864111. [Google Scholar] [CrossRef] [PubMed]
[31] Peters, R., Stephan, C., Jung, K., Lein, M., Friedersdorff, F. and Maxeiner, A. (2021) Comparison of PHI and PHI Density for Prostate Cancer Detection in a Large Retrospective Caucasian Cohort. Urologia Internationalis, 106, 878-883. [Google Scholar] [CrossRef] [PubMed]
[32] Friedl, A., Stangl, K., Bauer, W., Kivaranovic, D., Schneeweiss, J., Susani, M., et al. (2017) Prostate-Specific Antigen Parameters and Prostate Health Index Enhance Prostate Cancer Prediction with the In-Bore 3-T Magnetic Resonance Imaging-Guided Transrectal Targeted Prostate Biopsy after Negative 12-Core Biopsy. Urology, 110, 148-153. [Google Scholar] [CrossRef] [PubMed]
[33] 孙浩瑜, 姜鑫, 陈守臻, 等. 多参数磁共振联合前列腺健康指数对PSA灰区临床有意义前列腺癌的诊断价值[J]. 山东大学学报∙医学版, 2022, 60(6): 46-50.
[34] Fan, Y.H., Pan, P.H., Cheng, W.M., Wang, H., Shen, S., Liu, H., et al. (2021) The Prostate Health Index Aids Multi-Parametric MRI in Diagnosing Significant Prostate Cancer. Scientific Reports, 11, Article No. 1286. [Google Scholar] [CrossRef] [PubMed]
[35] 李赵, 钱文斌, 吴伟. 前列腺健康指数评分及血清β2-微球蛋白对前列腺特异性抗原灰区前列腺癌的诊断价值[J]. 泌尿外科杂志∙电子版, 2021(1): 26-28.
[36] Vigneswaran, H.T., Eklund, M., Discacciati, A., Nordström, T., Hubbard, R.A., Perlis, N., et al. (2024) Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial. Journal of Clinical Oncology, 42, 3806-3816. [Google Scholar] [CrossRef] [PubMed]
[37] Ruan, X., Huang, D., Huang, J., Huang, J., Zhan, Y., Wu, Y., et al. (2023) The Combined Effect of Polygenic Risk Score and Prostate Health Index in Chinese Men Undergoing Prostate Biopsy. Journal of Clinical Medicine, 12, Article No. 1343. [Google Scholar] [CrossRef] [PubMed]
[38] Stovsky, M., Klein, E.A., Chait, A., Manickam, K., Stephenson, A.J., Wagner, M., et al. (2019) Clinical Validation of IsoPSA™, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer. Journal of Urology, 201, 1115-1120. [Google Scholar] [CrossRef] [PubMed]
[39] Klein, E.A., Partin, A., Lotan, Y., Baniel, J., Dineen, M., Hafron, J., et al. (2022) Clinical Validation of IsoPSA, a Single Parameter, Structure-Focused Assay for Improved Detection of Prostate Cancer: A Prospective, Multicenter Study. Urologic Oncology: Seminars and Original Investigations, 40, 408.e9-408.e18. [Google Scholar] [CrossRef] [PubMed]
[40] Wei, J.T., Barocas, D., Carlsson, S., Coakley, F., Eggener, S., Etzioni, R., et al. (2023) Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. Journal of Urology, 210, 46-53. [Google Scholar] [CrossRef] [PubMed]
[41] Wei, J.T., Barocas, D., Carlsson, S., Coakley, F., Eggener, S., Etzioni, R., et al. (2023) Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. Journal of Urology, 210, 54-63. [Google Scholar] [CrossRef] [PubMed]
[42] Cornford, P., van den Bergh, R.C.N., Briers, E., Van den Broeck, T., Brunckhorst, O., Darraugh, J., et al. (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 86, 148-163. [Google Scholar] [CrossRef] [PubMed]
[43] Chiu, P.K., Ng, C.F., Semjonow, A., Zhu, Y., Vincendeau, S., Houlgatte, A., et al. (2019) A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges Is Needed for European and Asian Settings. European Urology, 75, 558-561. [Google Scholar] [CrossRef] [PubMed]
[44] Ye, C., Ho, J., Kim, D.H., Song, S.H., Kim, H., Lee, H., et al. (2022) The Prostate Health Index and Multi-Parametric MRI Improve Diagnostic Accuracy of Detecting Prostate Cancer in Asian Populations. Investigative and Clinical Urology, 63, 631-638. [Google Scholar] [CrossRef] [PubMed]
[45] Hsieh, P., Li, W., Lin, W., Chang, H., Chang, C., Huang, C., et al. (2019) Combining Prostate Health Index and Multiparametric Magnetic Resonance Imaging in the Diagnosis of Clinically Significant Prostate Cancer in an Asian Population. World Journal of Urology, 38, 1207-1214. [Google Scholar] [CrossRef] [PubMed]
[46] 曾纪宁, 胡峰, 郑巍, 等. 前列腺健康指数对PSA 4-10 μg/L澳门本地亚洲人种前列腺癌的诊断价值[J]. 中华男科学杂志, 2021, 27(9): 803-808.
[47] Chen, R., Ren, S., Yiu, M.K., Fai, N.C., Cheng, W.S., Ian, L.H., et al. (2014) Prostate Cancer in Asia: A Collaborative Report. Asian Journal of Urology, 1, 15-29. [Google Scholar] [CrossRef] [PubMed]
[48] Bouttell, J., Teoh, J., Chiu, P.K., Chan, K.S., Ng, C., Heggie, R., et al. (2019) Economic Evaluation of the Introduction of the Prostate Health Index as a Rule-Out Test to Avoid Unnecessary Biopsies in Men with Prostate Specific Antigen Levels of 4-10 in Hong Kong SAR. PLOS ONE, 14, e0215279. [Google Scholar] [CrossRef] [PubMed]
[49] Huang, D., Yang, X., Wu, Y., Lin, X., Xu, D., Na, R., et al. (2020) Cost-Effectiveness Analysis of Prostate Health Index in Decision Making for Initial Prostate Biopsy. Frontiers in Oncology, 10, Article ID: 565382. [Google Scholar] [CrossRef] [PubMed]
[50] Ferro, M., Crocetto, F., Bruzzese, D., Imbriaco, M., Fusco, F., Longo, N., et al. (2021) Prostate Health Index and Multiparametric MRI: Partners in Crime Fighting Overdiagnosis and Overtreatment in Prostate Cancer. Cancers, 13, Article No. 4723. [Google Scholar] [CrossRef] [PubMed]
[51] 刘世贤, 李顺平, 窦蕾, 等. 国内前列腺癌经济学评价研究现状[J]. 医学与社会, 2023, 36(1): 75-79.

为你推荐